Startups
Reunion Neuroscience
Reunion Neuroscience is a Morristown, New Jersey clinical-stage biotechnology company developing psychedelic-inspired treatments for mental health disorders. Its lead investigational drug, luvesilocin (formerly RE104), is a patented prodrug of 4-OH-DiPT that targets the serotonin 2A receptor and is designed for subcutaneous administration with a shorter acute psychedelic experience. The company is studying postpartum depression, adjustment disorder and generalized anxiety disorder. It reported positive Phase 2 postpartum depression results and received FDA Breakthrough Therapy Designation in February 2026; the drug remains investigational. Reunion became privately held after its acquisition by an MPM BioImpact affiliate in 2023. Its Series A financing, initially announced at USD103 million in May 2024, reached USD133 million at the final tranche closing in September 2025. Sahil Kirpekar became President and CEO in June 2026.
Team
 Alan SchatzbergScientific Advisory Board Member |
 Anita H. ClaytonScientific Advisory Board Member |
 Ansbert GadickeBoard Member |
 Beatrix TaylorSenior Vice President, Clinical Development & Regulatory Affairs |
 Brian ShusterBoard Member |
 Charles NemeroffScientific Advisory Board Member |
 Edward SmithChief Financial Officer |
 Ellen LubmanBoard Member |
 Jerry RosenbaumScientific Advisory Board Member |
 Kristina DeligiannidisScientific Advisory Board Member |
 Manish AgrawalScientific Advisory Board Member |
Mark PollackChief Medical Officer |
 Mark TheeuwesChief Operating Officer |
 Matthew W. JohnsonScientific Advisory Board Member |
 Michael Van AmeringenScientific Advisory Board Member |
 Natalie SacksBoard Member |
 Nathan BrysonChief Scientific Officer |
 Peter HendricksScientific Advisory Board Member |
 Pini OrbachBoard Member |
 Rachel YehudaScientific Advisory Board Member |
 Robert AlexanderScientific Advisory Board Member |
 Sahil KirpekarPresident & Chief Executive Officer ยท Board Director |
 Sheryl KingsbergScientific Advisory Board Member |
 Yvan BeaussantScientific Advisory Board Member |